Skip to Content
Merck
  • Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy.

Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy.

Bioorganic & medicinal chemistry (2008-08-12)
Mickaël Thomas, Jonathan Clarhaut, Isabelle Tranoy-Opalinski, Jean-Pierre Gesson, Joëlle Roche, Sébastien Papot
ABSTRACT

Two glucuronide prodrugs of the histone deacetylase inhibitor CI-994 were synthesized. These compounds were found to be soluble in aqueous media and stable under physiological conditions. The carbamoyl derivatisation of CI-994 significantly decreased its toxicity towards NCI-H661 lung cancer cells. Prodrug incubation with beta-glucuronidase in the culture media led efficiently to the release of the parent drug and thereby restoring its ability to decrease cell proliferation, to inhibit HDAC and to induce E-Cadherin expression.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
β-Glucuronidase from Escherichia coli, aqueous glycerol solution, ≥5,000,000 units/g protein, pH 6.8 (biuret)
Sigma-Aldrich
CI−994, ≥98% (HPLC), powder